Tocilizumab given through fluid-draining tubes for advanced cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called tocilizumab, which is given through the tube that drains fluid from your chest or belly. The goal is to see if it can help control cancer-related fluid buildup and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 89 years old.
- Your cancer has spread and caused fluid buildup in your chest or belly (doctor has confirmed this).
- You are already scheduled to get a tube (catheter) placed to drain this fluid.
- You are able to take care of most daily activities (ECOG score 0-2).
- You do not have a serious infection, autoimmune disease, or known allergy to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment using your own immune cells (T cells) to fight cancer that has spread to the lining of the lung and is causing fluid buildup. It may help if other standard treatments have stopped working.
This trial tests a new therapy using your own immune cells (called TILs) to treat cancer that has spread to the lining of the lungs. The goal is to see if these cells can shrink tumors and help you feel better.
This early-stage trial tests a new drug (WSK-IM02) delivered directly into the space around your lungs or abdomen to treat fluid buildup caused by advanced cancer. The drug is designed to reduce this fluid and improve your symptoms and quality of life.
This trial tests three drugs (bevacizumab, serplulimab, and rmhTNF-NC) given together to treat fluid buildup in the belly caused by digestive system cancers. It’s for people whose ascites has not improved after standard treatments.
This trial studies whether an immune-blocking drug placed directly into the belly cavity can help people with cancer-caused fluid buildup (malignant ascites) from stomach, pancreas, or bile-duct cancers. It may help shrink the fluid and slow the illness, but you must meet specific safety and treatment-history requirements.
This trial tests a combination of a modified TNF drug (rmhTNF-NC), an immunotherapy (tislelizumab), and radiation therapy for people with digestive system cancers that have caused moderate or large amounts of fluid buildup in the belly (ascites) and when standard treatments have stopped working. The goal is to see if this approach can help control the ascites and improve symptoms.
Hear when a new Malignant Pleural Effusion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.